vs
Side-by-side financial comparison of CG Oncology, Inc. (CGON) and KOSS CORP (KOSS). Click either name above to swap in a different company.
KOSS CORP is the larger business by last-quarter revenue ($2.9M vs $2.3M, roughly 1.2× CG Oncology, Inc.). KOSS CORP runs the higher net margin — -19.8% vs -1779.0%, a 1759.3% gap on every dollar of revenue. On growth, CG Oncology, Inc. posted the faster year-over-year revenue change (409.2% vs -19.6%). KOSS CORP produced more free cash flow last quarter ($-1.1M vs $-36.2M).
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
Koss Corporation is a company in Milwaukee, Wisconsin, US that manufactures headphones. The company created the first high-fidelity stereo headphones in 1958.
CGON vs KOSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.3M | $2.9M |
| Net Profit | $-41.3M | $-565.4K |
| Gross Margin | — | 29.0% |
| Operating Margin | -2097.3% | -35.5% |
| Net Margin | -1779.0% | -19.8% |
| Revenue YoY | 409.2% | -19.6% |
| Net Profit YoY | -29.9% | -700.6% |
| EPS (diluted) | $-0.52 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3M | $2.9M | ||
| Q3 25 | $1.7M | $4.1M | ||
| Q2 25 | $0 | $3.1M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | $456.0K | $3.6M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $2.9M | ||
| Q1 24 | $529.0K | $2.6M |
| Q4 25 | $-41.3M | $-565.4K | ||
| Q3 25 | $-43.8M | $243.7K | ||
| Q2 25 | $-41.4M | $-232.7K | ||
| Q1 25 | — | $-316.7K | ||
| Q4 24 | $-31.8M | $94.1K | ||
| Q3 24 | — | $-419.5K | ||
| Q2 24 | — | $-110.4K | ||
| Q1 24 | $-16.9M | $-313.8K |
| Q4 25 | — | 29.0% | ||
| Q3 25 | — | 40.0% | ||
| Q2 25 | — | 36.0% | ||
| Q1 25 | — | 39.0% | ||
| Q4 24 | — | 39.5% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 40.4% | ||
| Q1 24 | — | 31.9% |
| Q4 25 | -2097.3% | -35.5% | ||
| Q3 25 | -3069.0% | -1.1% | ||
| Q2 25 | — | -14.2% | ||
| Q1 25 | — | -18.7% | ||
| Q4 24 | -8344.1% | -4.0% | ||
| Q3 24 | — | -19.9% | ||
| Q2 24 | — | -11.0% | ||
| Q1 24 | -4247.4% | -23.1% |
| Q4 25 | -1779.0% | -19.8% | ||
| Q3 25 | -2629.5% | 6.0% | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | -11.4% | ||
| Q4 24 | -6973.7% | 2.6% | ||
| Q3 24 | — | -13.1% | ||
| Q2 24 | — | -3.8% | ||
| Q1 24 | -3200.8% | -11.9% |
| Q4 25 | $-0.52 | $-0.06 | ||
| Q3 25 | $-0.57 | $0.03 | ||
| Q2 25 | $-0.54 | $-0.02 | ||
| Q1 25 | — | $-0.03 | ||
| Q4 24 | $-0.47 | $0.01 | ||
| Q3 24 | — | $-0.05 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | $-0.36 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $742.2M | $15.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $752.6M | $30.3M |
| Total Assets | $791.6M | $36.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $742.2M | $15.5M | ||
| Q3 25 | $680.3M | $16.5M | ||
| Q2 25 | $661.1M | $15.7M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | $742.0M | $9.7M | ||
| Q3 24 | — | $11.9M | ||
| Q2 24 | — | $14.9M | ||
| Q1 24 | $566.5M | $9.9M |
| Q4 25 | $752.6M | $30.3M | ||
| Q3 25 | $687.6M | $30.9M | ||
| Q2 25 | $670.4M | $30.6M | ||
| Q1 25 | — | $30.7M | ||
| Q4 24 | $733.4M | $31.0M | ||
| Q3 24 | — | $30.8M | ||
| Q2 24 | — | $31.1M | ||
| Q1 24 | $568.9M | $31.1M |
| Q4 25 | $791.6M | $36.8M | ||
| Q3 25 | $729.9M | $37.7M | ||
| Q2 25 | $701.4M | $37.2M | ||
| Q1 25 | — | $37.3M | ||
| Q4 24 | $754.8M | $37.4M | ||
| Q3 24 | — | $38.1M | ||
| Q2 24 | — | $37.2M | ||
| Q1 24 | $579.1M | $37.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-36.2M | $-760.8K |
| Free Cash FlowOCF − Capex | $-36.2M | $-1.1M |
| FCF MarginFCF / Revenue | -1560.0% | -37.5% |
| Capex IntensityCapex / Revenue | 0.3% | 10.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-124.1M | $-546.7K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-36.2M | $-760.8K | ||
| Q3 25 | $-38.9M | $762.6K | ||
| Q2 25 | $-28.0M | $-534.9K | ||
| Q1 25 | — | $370.4K | ||
| Q4 24 | $-20.7M | $-252.0K | ||
| Q3 24 | — | $201.6K | ||
| Q2 24 | — | $-174.0K | ||
| Q1 24 | $-26.0M | $328.6K |
| Q4 25 | $-36.2M | $-1.1M | ||
| Q3 25 | $-39.0M | $761.5K | ||
| Q2 25 | $-28.0M | $-541.8K | ||
| Q1 25 | — | $306.2K | ||
| Q4 24 | $-20.9M | $-314.3K | ||
| Q3 24 | — | $-155.6K | ||
| Q2 24 | — | $-174.8K | ||
| Q1 24 | $-26.0M | $269.3K |
| Q4 25 | -1560.0% | -37.5% | ||
| Q3 25 | -2340.4% | 18.7% | ||
| Q2 25 | — | -17.6% | ||
| Q1 25 | — | 11.0% | ||
| Q4 24 | -4577.0% | -8.8% | ||
| Q3 24 | — | -4.9% | ||
| Q2 24 | — | -6.0% | ||
| Q1 24 | -4919.5% | 10.2% |
| Q4 25 | 0.3% | 10.9% | ||
| Q3 25 | 5.8% | 0.0% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 45.8% | 1.8% | ||
| Q3 24 | — | 11.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | 2.3% | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.13× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -2.68× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
